A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma
Clinical trial NCT04244656 · TERMINATED
Trial details
- NCT number
- NCT04244656
- Sponsor
- CRISPR Therapeutics AG
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-01-22
- Primary completion
- 2024-01-04
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.